


SIXTEENTH CONGRESS OF THE REPUBLIC)
OF THE PHILIPPINES)
Second Regular Session)



15 MAY 26 P5:18

SENATE

P.S. Res. No. 1382

RECEIVED BY: W

Introduced by Senator Manuel "Lito" M. Lapid

RESOLUTION

DIRECTING THE SENATE COMMITTEE ON HEALTH AND DEMOGRAPHY AND OTHER APPROPRIATE SENATE COMMITTEES TO CONDUCT AN INQUIRY, IN AID OF LEGISLATION, ON THE DEVELOPMENTS IN THE PHILIPPINE PHARMACEUTICAL SECTOR SINCE THE ADOPTION AND IMPLEMENTATION BY THE FOOD AND DRUG ADMINISTRATION OF "THE MEXICO CITY PRINCIPLES FOR VOLUNTARY CODES OF BUSINESS ETHICS IN THE BIOPHARMACEUTICAL SECTOR"

WHEREAS, Section 11, Article XIII of the Philippine Constitution affirms that the State shall "adopt an integrated and comprehensive approach to health development which shall endeavor to make essential goods, health and other social services available to all the people at affordable cost.";

WHEREAS, Section 12, Article XIII of the Philippine Constitution further states that the State shall "establish and maintain an effective food and drug regulatory system and undertake appropriate health manpower development and research, responsive to the country's health needs and problems.";

WHEREAS, endorsed during the 19th Asia Pacific Economic Cooperation (APEC) Economic Leader Meeting in Hawaii, "The Mexico City Principles for Voluntary Code of Business Ethics for the Biopharmaceutical Sector" or simply the Mexico City Principles (MCP) serves as a guide for the ethical conduct and interaction between the healthcare sector and the biopharmaceutical industry to ensure that medical decisions are made in the best interests of the patients;

WHEREAS, on September 5, 2013, the Food and Drugs Administration (FDA) issued FDA Circular No. 2013-024 adopting and implementing "The Mexico City Principles, making it applicable to all drugs establishment regulated by the FDA, healthcare professionals, as well as other stakeholders like media and advertisement firms;

WHEREAS, there is a need to inquire into the developments into the Pharmaceutical industry nearing two years after the FDA issued Circular No. 2013-024 to identify potential legislative measures to see to it that concerned stakeholders abide by its doctrines for the benefit of Filipino patients.

NOW, THEREFORE, BE IT RESOLVED, as it is hereby resolved, That the Philippine Senate directs the Senate Committee on Health and Demography and other appropriate Senate committees to conduct an inquiry, in aid of legislation, on the developments in the Philippine pharmaceutical sector since the adoption and implementation by the Food and Drug Administration of "The Mexico City Principles for Voluntary Codes of Business Ethics in the Biopharmaceutical Sector".

Adopted,



MANUEL "LITO" M. LAPID